Cancer and autoimmunity: Harnessing longitudinal cohorts to probe the link

Best Practice and Research: Clinical Rheumatology

Volumn 30, Issue 1, 2016, Pages 53-62

  Egiziano, Giordano ^a   Bernatsky, Sasha ^b   Shah, Ami A ^c  

^a ROYAL VICTORIA HOSPITAL   (Canada)

^b MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^c JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Autoimmunity; Cancer; Epidemiology; Observational cohorts

Indexed keywords

AUTOIMMUNITY; CANCER RISK; COHORT ANALYSIS; HUMAN; KNOWLEDGE BASE; LONGITUDINAL STUDY; MALIGNANT NEOPLASTIC DISEASE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; REVIEW; RHEUMATIC DISEASE; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; AUTOIMMUNE DISEASE; IMMUNOLOGY; INFLAMMATION; NEOPLASM;

AUTOIMMUNE DISEASES; AUTOIMMUNITY; HUMANS; INFLAMMATION; NEOPLASMS; RHEUMATIC DISEASES;

EID: 84963613064     PISSN: 15216942     EISSN: 15321770     Source Type: Journal    
DOI: 10.1016/j.berh.2016.03.001     Document Type: Review

References (77)

1. Shah, A.A., Casciola-Rosen, L., Rosen, A., Review: cancer-induced autoimmunity in the rheumatic diseases. Arthritis Rheumatol 67:2 (2015), 317–326.
2. [2] Simon, T.A., Thompson, A., Gandhi, K.K., et al. Incidence of malignancy in adult patients with rheumatoid arthritis: a meta-analysis. Arthritis Res Ther, 17, 2015, 212.
3. Bernatsky, S., Ramsey-Goldman, R., Labrecque, J., et al. Cancer risk in systemic lupus: an updated international multi-centre cohort study. J Autoimmun 42 (2013), 130–135.
4. [4] Onishi, A., Sugiyama, D., Kumagai, S., Morinobu, A., Cancer incidence in systemic sclerosis: meta-analysis of population-based cohort studies. Arthritis Rheum 65:7 (2013), 1913–1921.
5. [5] Yang, Z., Lin, F., Qin, B., et al. Polymyositis/dermatomyositis and malignancy risk: a metaanalysis study. J Rheumatol 42:2 (2015), 282–291.
6. [6] Liang, Y., Yang, Z., Qin, B., Zhong, R., Primary Sjogren's syndrome and malignancy risk: a systematic review and meta-analysis. Ann Rheum Dis 73:6 (2014), 1151–1156.
7. [7] Shang, W., Ning, Y., Xu, X., et al. Incidence of cancer in ANCA-associated vasculitis: a meta-analysis of observational studies. PLoS One, 10(5), 2015, e0126016.
8. [8] Balkwill, F., Mantovani, A., Inflammation and cancer: back to Virchow?. Lancet 357:9255 (2001), 539–545.
9. [9] Baimpa, E., Dahabreh, I.J., Voulgarelis, M., Moutsopoulos, H.M., Hematologic manifestations and predictors of lymphoma development in primary Sjogren syndrome: clinical and pathophysiologic aspects. Medicine (Baltimore) 88:5 (2009), 284–293.
10. [10] Baldini, C., Pepe, P., Luciano, N., et al. A clinical prediction rule for lymphoma development in primary Sjogren's syndrome. J Rheumatol 39:4 (2012), 804–808.
11. [11] Theander, E., Vasaitis, L., Baecklund, E., et al. Lymphoid organisation in labial salivary gland biopsies is a possible predictor for the development of malignant lymphoma in primary Sjogren's syndrome. Ann Rheum Dis 70:8 (2011), 1363–1368.
12. [12] Llorca, J., Lopez-Diaz, M.J., Gonzalez-Juanatey, C., et al. Persistent chronic inflammation contributes to the development of cancer in patients with rheumatoid arthritis from a defined population of northwestern Spain. Semin Arthritis Rheum 37:1 (2007), 31–38.
13. [13] Hellgren, K., Iliadou, A., Rosenquist, R., et al. Rheumatoid arthritis, treatment with corticosteroids and risk of malignant lymphomas: results from a case–control study. Ann Rheum Dis 69:4 (2010), 654–659.
14. [14] Peters-Golden, M., Wise, R.A., Hochberg, M., et al. Incidence of lung cancer in systemic sclerosis. J Rheumatol 12:6 (1985), 1136–1139.
15. [15] Abu-Shakra, M., Guillemin, F., Lee, P., Cancer in systemic sclerosis. Arthritis Rheum 36:4 (1993), 460–464.
16. [16] Bobba, R.K., Holly, J.S., Loy, T., Perry, M.C., Scar carcinoma of the lung: a historical perspective. Clin Lung Cancer 12:3 (2011), 148–154.
17. [17] Yu, Y.Y., Pinsky, P.F., Caporaso, N.E., et al. Lung cancer risk following detection of pulmonary scarring by chest radiography in the prostate, lung, colorectal, and ovarian cancer screening trial. Arch Intern Med 168:21 (2008), 2326–2332 discussion 32.
18. [18] Monach, P.A., Arnold, L.M., Merkel, P.A., Incidence and prevention of bladder toxicity from cyclophosphamide in the treatment of rheumatic diseases: a data-driven review. Arthritis Rheum 62:1 (2010), 9–21.
19. [19] Faurschou, M., Sorensen, I.J., Mellemkjaer, L., et al. Malignancies in Wegener's granulomatosis: incidence and relation to cyclophosphamide therapy in a cohort of 293 patients. J Rheumatol 35:1 (2008), 100–105.
20. [20] Bichari, W., Bartiromo, M., Mohey, H., et al. Significant risk factors for occurrence of cancer after renal transplantation: a single center cohort study of 1265 cases. Transpl Proc 41:2 (2009), 672–673.
21. [21] Brewer, J.D., Colegio, O.R., Phillips, P.K., et al. Incidence of and risk factors for skin cancer after heart transplant. Arch Dermatol 145:12 (2009), 1391–1396.
22. [22] Marcen, R., Galeano, C., Fernandez-Rodriguez, A., et al. Effects of the new immunosuppressive agents on the occurrence of malignancies after renal transplantation. Transpl Proc 42:8 (2010), 3055–3057.
23. [23] Robson, R., Cecka, J.M., Opelz, G., et al. Prospective registry-based observational cohort study of the long-term risk of malignancies in renal transplant patients treated with mycophenolate mofetil. Am J Transpl 5:12 (2005), 2954–2960.
24. [24] Crane, G.M., Powell, H., Kostadinov, R., et al. Primary CNS lymphoproliferative disease, mycophenolate and calcineurin inhibitor usage. Oncotarget 6:32 (2015), 33849–33866.
25. [25] Wolfe, F., Michaud, K., Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study. Arthritis Rheum 56:9 (2007), 2886–2895.
26. [26] Mercer, L.K., Green, A.C., Galloway, J.B., et al. The influence of anti-TNF therapy upon incidence of keratinocyte skin cancer in patients with rheumatoid arthritis: longitudinal results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 71:6 (2012), 869–874.
27. [27] Moulis, G., Sommet, A., Bene, J., et al. Cancer risk of anti-TNF-alpha at recommended doses in adult rheumatoid arthritis: a meta-analysis with intention to treat and per protocol analyses. PLoS One, 7(11), 2012, e48991.
28. [28] Ramiro, S., Gaujoux-Viala, C., Nam, J.L., et al. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis 73:3 (2014), 529–535.
29. [29] Dreyer, L., Faurschou, M., Mogensen, M., Jacobsen, S., High incidence of potentially virus-induced malignancies in systemic lupus erythematosus: a long-term followup study in a Danish cohort. Arthritis Rheum 63:10 (2011), 3032–3037.
30. [30] Berger, C.C., Bokemeyer, C., Schneider, M., et al. Secondary Raynaud's phenomenon and other late vascular complications following chemotherapy for testicular cancer. Eur J Cancer 31A:13–14 (1995), 2229–2238.
31. [31] Bessis, D., Guillot, B., Legouffe, E., Guilhou, J.J., Gemcitabine-associated scleroderma-like changes of the lower extremities. J Am Acad Dermatol 51:2 Suppl. (2004), S73–S76.
32. [32] Clowse, M.E., Wigley, F.M., Digital necrosis related to carboplatin and gemcitabine therapy in systemic sclerosis. J Rheumatol 30:6 (2003), 1341–1343.
33. [33] Cohen, I.S., Mosher, M.B., O'Keefe, E.J., et al. Cutaneous toxicity of bleomycin therapy. Arch Dermatol 107:4 (1973), 553–555.
34. [34] Finch, W.R., Rodnan, G.P., Buckingham, R.B., et al. Bleomycin-induced scleroderma. J Rheumatol 7:5 (1980), 651–659.
35. [35] Alias, A., Rodriguez, E.J., Bateman, H.E., et al. Rheumatology and oncology: an updated review of rheumatic manifestations of malignancy and anti-neoplastictherapy. Bull NYU Hosp Jt Dis 70:2 (2012), 109–114.
36. [36] Ioannou, Y., Isenberg, D.A., Current evidence for the induction of autoimmune rheumatic manifestations by cytokine therapy. Arthritis Rheum 43:7 (2000), 1431–1442.
37. [37] Bronstein, Y., Ng, C.S., Hwu, P., Hwu, W.J., Radiologic manifestations of immune-related adverse events in patients with metastatic melanoma undergoing anti-CTLA-4 antibody therapy. AJR Am J Roentgenol 197:6 (2011), W992–W1000.
38. [38] Chan, M.M., Kefford, R.F., Carlino, M., et al. Arthritis and tenosynovitis associated with the anti-PD1 antibody pembrolizumab in metastatic melanoma. J Immunother 38:1 (2015), 37–39.
39. [39] Goldstein, B.L., Gedmintas, L., Todd, D.J., Drug-associated polymyalgia rheumatica/giant cell arteritis occurring in two patients after treatment with ipilimumab, an antagonist of ctla-4. Arthritis Rheumatol 66:3 (2014), 768–769.
40. [40] Sheik Ali, S., Goddard, A.L., Luke, J.J., et al. Drug-associated dermatomyositis following ipilimumab therapy: a novel immune-mediated adverse event associated with cytotoxic T-lymphocyte antigen 4 blockade. JAMA Dermatol 151:2 (2015), 195–199.
41. [41] Yoshioka, M., Kambe, N., Yamamoto, Y., et al. Case of respiratory discomfort due to myositis after administration of nivolumab. J Dermatol 42:10 (2015), 1008–1009.
42. [42] Colver, G.B., Rodger, A., Mortimer, P.S., et al. Post-irradiation morphoea. Br J Dermatol 120:6 (1989), 831–835.
43. [43] Varga, J., Haustein, U.F., Creech, R.H., et al. Exaggerated radiation-induced fibrosis in patients with systemic sclerosis. JAMA 265:24 (1991), 3292–3295.
44. Casciola-Rosen, L., Nagaraju, K., Plotz, P., et al. Enhanced autoantigen expression in regenerating muscle cells in idiopathic inflammatory myopathy. J Exp Med 201:4 (2005), 591–601.
45. [45] Fiorentino, D.F., Chung, L.S., Christopher-Stine, L., et al. Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1gamma. Arthritis Rheum 65:11 (2013), 2954–2962.
46. [46] Moinzadeh, P., Fonseca, C., Hellmich, M., et al. Association of anti-RNA polymerase III autoantibodies and cancer in scleroderma. Arthritis Res Ther, 16(1), 2014, R53.
47. [47] Shah, A.A., Hummers, L.K., Casciola-Rosen, L., et al. Examination of autoantibody status and clinical features associated with cancer risk and cancer-associated scleroderma. Arthritis Rheumatol 67:4 (2015), 1053–1061.
48. Shah, A.A., Rosen, A., Hummers, L., et al. Close temporal relationship between onset of cancer and scleroderma in patients with RNA polymerase I/III antibodies. Arthritis Rheum 62:9 (2010), 2787–2795.
49. [49] Hasegawa, M., Sato, S., Sakai, H., et al. Systemic sclerosis revealing T-cell lymphoma. Dermatology 198:1 (1999), 75–78.
50. [50] Juarez, M., Marshall, R., Denton, C., Evely, R., Paraneoplastic scleroderma secondary to hairy cell leukaemia successfully treated with cladribine. Rheumatology 47:11 (2008), 1734–1735.
51. [51] Shah, A.A., Casciola-Rosen, L., Cancer and scleroderma: a paraneoplastic disease with implications for malignancy screening. Curr Opin Rheumatol 27:6 (2015), 563–570.
52. [52] Mantovani, A., Allavena, P., Sica, A., Balkwill, F., Cancer-related inflammation. Nature 454:7203 (2008), 436–444.
53. [53] Karin, M., Lawrence, T., Nizet, V., Innate immunity gone awry: linking microbial infections to chronic inflammation and cancer. Cell 124:4 (2006), 823–835.
54. Bernatsky, S., Ramsey-Goldman, R., Joseph, L., et al. Lymphoma risk in systemic lupus: effects of disease activity versus treatment. Ann Rheum Dis 73:1 (2014), 138–142.
55. [55] Apor, E., O'Brien, J., Stephen, M., Castillo, J.J., Systemic lupus erythematosus is associated with increased incidence of hematologic malignancies: a meta-analysis of prospective cohort studies. Leuk Res 38:9 (2014), 1067–1071.
56. [56] Bernatsky, S., Ramsey-Goldman, R., Rajan, R., et al. Non-Hodgkin's lymphoma in systemic lupus erythematosus. Ann Rheum Dis 64:10 (2005), 1507–1509.
57. [57] Tessier Cloutier, B., Farinha, P., Bernatsky, S., et al. Cell of origin of diffuse large B-cell lymphoma (DLBCL) in patients with systemic lupus erythematosus (SLE). [abstract] Arthritis Rheumatol, 67(Suppl. 10), 2015.
58. [58] Goobie, G.C., Bernatsky, S., Ramsey-Goldman, R., Clarke, A.E., Malignancies in systemic lupus erythematosus: a 2015 update. Curr Opin Rheumatol 27:5 (2015), 454–460.
59. [59] Stohl, W., Therapeutic targeting of the BAFF/APRIL axis in systemic lupus erythematosus. Expert Opin Ther Targets 18:4 (2014), 473–489.
60. [60] Zollars, E., Fang, H., Bienkowska, J., et al. Only BAFF mRNA, not BAFF protein level in blood, is associated with SLE activity over one year. [abstract] Arthritis Rheumatol, 65(Suppl. 10), 2013.
61. [61] Karin, M., Cao, Y., Greten, F.R., Li, Z.W., NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2:4 (2002), 301–310.
62. Lofstrom, B., Backlin, C., Pettersson, T., et al. Expression of APRIL in diffuse large B cell lymphomas from patients with systemic lupus erythematosus and rheumatoid arthritis. J Rheumatol 38:9 (2011), 1891–1897.
63. [63] Draborg, A.H., Duus, K., Houen, G., Epstein-Barr virus in systemic autoimmune diseases. Clin Dev Immunol, 2013, 2013, 535738.
64. [64] Rasmussen, N.S., Draborg, A.H., Nielsen, C.T., et al. Antibodies to early EBV, CMV, and HHV6 antigens in systemic lupus erythematosus patients. Scand J Rheumatol 44:2 (2015), 143–149.
65. [65] Hanlon, P., Avenell, A., Aucott, L., Vickers, M.A., Systematic review and meta-analysis of the sero-epidemiological association between Epstein-Barr virus and systemic lupus erythematosus. Arthritis Res Ther, 16(1), 2014, R3.
66. [66] Kamel, O.W., van de Rijn, M., Hanasono, M.M., Warnke, R.A., Immunosuppression-associated lymphoproliferative disorders in rheumatic patients. Leuk Lymphoma 16:5–6 (1995), 363–368.
67. [67] Baecklund, E., Iliadou, A., Askling, J., et al. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum 54:3 (2006), 692–701.
68. [68] Hill, C.L., Zhang, Y., Sigurgeirsson, B., et al. Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet 357:9250 (2001), 96–100.
69. [69] Buchbinder, R., Forbes, A., Hall, S., et al. Incidence of malignant disease in biopsy-proven inflammatory myopathy. A population-based cohort study. Ann Intern Med 134:12 (2001), 1087–1095.
70. [70] Zantos, D., Zhang, Y., Felson, D., The overall and temporal association of cancer with polymyositis and dermatomyositis. J Rheumatol 21:10 (1994), 1855–1859.
71. [71] Colaci, M., Giuggioli, D., Vacchi, C., et al. Breast cancer in systemic sclerosis: results of a cross-linkage of an Italian Rheumatologic Center and a population-based Cancer Registry and review of the literature. Autoimmun Rev 13:2 (2014), 132–137.
72. [72] Airo, P., Ceribelli, A., Cavazzana, I., et al. Malignancies in Italian patients with systemic sclerosis positive for anti-RNA polymerase III antibodies. J Rheumatol 38:7 (2011), 1329–1334.
73. [73] Nikpour, M., Hissaria, P., Byron, J., et al. Prevalence, correlates and clinical usefulness of antibodies to RNA polymerase III in systemic sclerosis: a cross-sectional analysis of data from an Australian cohort. Arthritis Res Ther, 13(6), 2011, R211.
74. Joseph, C.G., Darrah, E., Shah, A.A., et al. Association of the autoimmune disease scleroderma with an immunologic response to cancer. Science 343:6167 (2014), 152–157.
75. [75] Hudson, M., Sharma, A., Bernstein, J., et al. Validity of self-reported comorbidities in systemic sclerosis. J Rheumatol 36:7 (2009), 1477–1480.
76. [76] Tessier-Cloutier, B., Clarke, A.E., Ramsey-Goldman, R., et al. Systemic lupus erythematosus and malignancies: a review article. Rheum Dis Clin North Am 40:3 (2014), 497–506 viii.
77. [77] Humphrey, L.L., Deffebach, M., Pappas, M., et al. Screening for lung cancer with low-dose computed tomography: a systematic review to update the US preventive services task force recommendation. Ann Intern Med 159:6 (2013), 411–420.